Colorectal adenocarcinoma

10 trials 3 recruiting MedDRA PT
10 Registered trials
3 Recruiting
10 Unique sponsors
24 Unique IMPs
5 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 5
N Neurology/Psychiatry (ATC N) 1
B Haematology (ATC B) 1
— ATC code not specified 4
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 6 substances
Antibody-drug conjugate (ADC) 2 substances
Antimetabolite 2 substances
Monoclonal antibody (immune) 2 substances
Checkpoint inhibitor (CTLA-4) 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Colony-stimulating factor 1 substance
Supportive / rescue 1 substance
Platinum compound 1 substance
Taxane 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Checkpoint inhibitor (PD-L1) 1 substance
Kinase inhibitor 1 substance
Monoclonal antibody (chimeric) 1 substance
RAF/BRAF inhibitor 1 substance
Monoclonal antibody 1 substance
Phase III: 2 Phase II: 5 Phase I/II: 1 Phase I (Other): 1 Phase I (First in Human): 1

Filter these 10 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 10 trials

Phase III

2 trials
  • Amgen Inc. Commercial
    ROMIPLOSTIM
    2023-507148-35-00 8 countries 2019 n=60
    Ended
  • Fundacion Para La Investigacion Biomedica De Cordoba Academic
    IMP not specified
    2025-520471-29-00 1 country n=1,083
    Pending

Phase II

5 trials
  • Seagen Inc. Commercial
    PEMBROLIZUMAB; TISOTUMAB VEDOTIN
    2023-503812-34-00 4 countries 2019 n=79
    Ended
  • AIO-Studien gGmbH Academic
    ATEZOLIZUMAB; MYCOBATERIUM OBUENSE, STRAIN NCTC 13365, HEAT-KILLED
    2024-515224-37-00 1 country 2023 n=80
    Ended
  • Asociacion Grupo Tratamiento De Tumores Digestivos Academic
    BINIMETINIB; CETUXIMAB; ENCORAFENIB
    2022-502413-29-00 1 country 2024 n=70
    Recruiting
  • Fondazione GONO G.I. Academic
    4-[1-[[6-[[4-(TRIFLUOROMETHYL)PHENYL]METHYL]-6-AZASPIRO[2.5]OCTANE-7-CARBONYL]AMINO]CYCLOPROPYL]BENZOIC ACID; AMIVANTAMAB; BALSTILIMAB; BOTENSILIMAB; TRASTUZUMAB DERUXTECAN
    2022-501308-90-00 1 country 2023 n=112
    Recruiting
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic
    IMP not specified
    2023-508615-24-00 1 country 2024 n=25
    Ended

Phase I/II

1 trial
  • Enliven Therapeutics Inc. Commercial
    CAPECITABINE; ELVN-002-1; ERIBULIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PACLITAXEL; TRASTUZUMAB
    2023-509716-29-00 5 countries 2024 n=156
    Ended

Phase I (Other)

1 trial
  • Incyte Corp. Commercial
    INCB099280; IPILIMUMAB
    2023-503243-34-00 3 countries n=23
    Ended

Phase I (First in Human)

1 trial
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Incyte Corp. Commercial 1 Phase I (Other) 0
Seagen Inc. Commercial 1 Phase II 0
Amgen Inc. Commercial 1 Phase III 0
BioNTech SE Commercial 1 Phase I (First in Human) 1
Enliven Therapeutics Inc. Commercial 1 Phase I/II 0
AIO-Studien gGmbH Academic 1 Phase II 0
Asociacion Grupo Tratamiento De Tumores Digestivos Academic 1 Phase II 1
Fondazione GONO G.I. Academic 1 Phase II 1
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic 1 Phase II 0
Fundacion Para La Investigacion Biomedica De Cordoba Academic 1 Phase III 0
New trials by year
2019
2
2023
2
2024
3
2026
1
← All indication landscapes